-+ 0.00%
-+ 0.00%
-+ 0.00%
Greenwich Lifesciences To Present Two FLAMINGO-01 Trial Abstracts At SABCS 2026
Share
Listen to the news

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for publication at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2026 along with two corresponding poster presentations.

The SABCS 2026 will be held from December 8-11, 2026. The posters will be presented on December 9, 2026 during the poster sessions for ongoing clinical trials and late breaking abstracts, with both posters being authored by the Steering Committee of FLAMINGO-01.

The posters will be provided on the Company's website during the conference when permitted to do so by SABCS. In addition, the following has been updated on the Company's website: Corporate slides, FLAMINGO-01 Phase III trial design, corporate presentation from investor conference, fireside chat, analyst commentary, interview which aired on Bloomberg/CNBC TV, and a patient and doctor interview at a clinical site participating in FLAMINGO-01.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending